A national effort to recall carcinogen-tainted batches of the popular blood pressure drug losartan has once again expanded, growing to include one lot of the medication distributed by Legacy Pharmaceutical Packaging, LLC.

Antibiotic use—particularly regimens that last for two months or more—was linked to an increased risk of CVD in a recent study of nearly 36,500 older women.

Five milligrams of rivaroxaban per day added to a patient’s standard therapy for heart failure (HF) and coronary artery disease (CAD) could reduce that patient’s risk of future thromboembolic events, researchers reported in JAMA Cardiology April 24.

Pennsylvania-based health company Orchestra BioMed has obtained FDA breakthrough device designation for its Virtue sirolimus-eluting balloon (SEB), according to a statement issued April 24.

Around a quarter of heart patients who undergo percutaneous coronary intervention (PCI) are readmitted to the hospital for unplanned reasons within six months of their procedure, researchers report in JACC: Cardiovascular Interventions.

The FDA’s Circulatory System Devices Panel of the Medical Devices Advisory Committee will meet in mid-June to discuss recent controversies and safety practices surrounding paclitaxel-coated and -eluting medical devices, according to a notice posted April 22.

Boston Scientific’s LOTUS Edge Aortic Valve System was cleared by the FDA April 23 for use in high-risk surgical candidates with severe aortic stenosis.

The American Academy of Pediatrics’ (AAP) updated blood pressure guidelines classify more kids in higher BP categories and can more accurately predict which children are prone to heart disease later in life, an extensive analysis of the Bogalusa Heart Study has found.